22nd Jan 2007 07:01
AGI Therapeutics plc22 January 2007 AGI Therapeutics plc appoints strong Medical Advisory Panel Dublin, Ireland, 22nd January 2007 - AGI Therapeutics plc ("AGI" or the"Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused ongastrointestinal drug products, today announces the appointment of a MedicalAdvisory Panel of international experts in the field of gastroenterology. The panel, which has already had its first meeting, advises management on avariety of subjects, providing input and insight on therapeutic areas ofinterest to the Company and assisting the Company in making informed decisionswith regard to the future development of its clinical programmes. The members of the Medical Advisory Panel are; Professor Eamonn Quigley (Professor of Medicine and Human Physiology, NationalUniversity of Ireland, University College Cork), Dr. Philip Schoenfeld (Associate Professor of Medicine, University of MichiganMedical School), Dr. William Chey, (Associate Professor of Medicine, University of MichiganMedical School), Dr. William Sandborn (Professor of Medicine, Division of Gastroenterology andHepatology, Mayo Clinic) and, Dr. Jan Tack (Professor of Medicine, Division of Gastroenterology, KatholiekeUniversiteit Leuven) Commenting on the establishment of this panel, Dr. John Devane, CEO of AGI said: "I am very pleased that we have been able to assemble a panel of internationalexperts of this calibre. I believe the combined expertise, knowledge and insightof our Medical Advisory Panel is critical in helping guide the medical/clinicaldevelopment of our product portfolio. We have already benefited from theirrecommendations and look forward to their continued input and advice on currentand potential product candidates." Contact Information: AGI Therapeutics plc.Tel: +353 1 449 3254David Kelly, Chief Financial Officer Financial Dynamics - UKTel: +44 (0) 20 7269 7182Anna Keeble Financial Dynamics - IrelandTel: +353 1 663 3607Aisling Garvey For further information please see www.agitherapeutics.com About AGI Therapeutics plc AGI is a speciality pharmaceutical company which is focused on the developmentand commercialisation of differentiated drug products for gastrointestinal (''GI'') diseases and disorders. AGI's common shares are listed on the AlternativeInvestment Market of the London Stock Exchange ("AIM") and on the IrishEnterprise Exchange of the Irish Stock Market ("IEX") as "AGI". The Company has a portfolio of product candidates derived from the KnownMolecular Entity (''KME'') approach to drug re-profiling and development. KME isa re-profiling methodology used by the Company to identify existing therapeuticdrugs which typically have been marketed for a number of years, have establishedsafety profiles and can be developed for new clinical indications or withimproved profiles in their existing clinical indications. In this way, theCompany seeks to reduce the risk, time and cost of new product development ascompared to the development of new chemical entities. AGI has developed a range of product candidates to treat a variety of prevalentGI diseases and disorders, including irritable bowel syndrome (IBS), dyspepsia,ulcerative colitis and gastro-esophageal reflux disease (GERD). The Company istargeting areas of the GI therapeutic drug products market for its productcandidates where there are currently unmet medical needs or where theeffectiveness of existing drug therapies can be further improved. The Company has clinical stage product candidates which are either isomers ornew drug delivery formulations of existing approved drugs, and which haveestablished safety and tolerability profiles in their currently approvedclinical indications. AGI intends to complete its ongoing clinical trials and, dependent on theresults of these trials, the Company will initiate late stage clinicaldevelopment of lead product candidates and will also seek to enter intolicensing and development agreements with pharmaceutical companies so as toenhance the global market reach for its products and achieve optimal revenue andvalue opportunities for the Company. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Potentially Ai